GlassScriptPhysician profile
Vincent M Gemelli
NPI 1982664876
$16,510.67
in general payments reported to CMS, 2019-2025
58 companies · $3,182 in 2025
The $3,182 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,610 · 2022: $3,036 · 2023: $3,661 · 2024: $4,021 · 2025: $3,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,848.30 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,459.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,459.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,112.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $917.45 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $915.83 | 2021-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $889.46 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $853.00 | 2021-2025 | |
| Pfizer INC. | $704.08 | 2021-2025 | |
| Amgen INC. | $612.45 | 2021-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $588.56 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.40 | 2021-2025 | Jardiance, Tradjenta |
| Lundbeck LLC | $553.21 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.06 | 2021-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.64 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $367.83 | 2022-2024 | Qelbree, Qelbree |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $366.86 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $350.40 | 2021-2025 | Verquvo, Gardasil 9, Belsomra |
| Phathom Pharmaceuticals, INC. | $334.01 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $328.59 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $254.77 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $248.12 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $228.12 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $193.96 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $179.43 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $171.11 | 2021-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $170.17 | 2022 | |
| Aimmune Therapeutics, INC. | $166.04 | 2025 | Zenpep |
| Idorsia Pharmaceuticals US INC | $150.46 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $122.64 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $96.88 | 2021-2022 | |
| Dexcom, INC. | $88.14 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $87.78 | 2021-2024 | Licart, Tirosint, Tirosint |
| Tolmar, INC. | $83.95 | 2023-2025 | Jatenzo |
| Mannkind Corporation | $75.21 | 2021-2022 | |
| Corium, LLC | $57.81 | 2023-2025 | Azstarys |
| Ucb, INC. | $54.60 | 2024 | Nayzilam |
| Mylan Specialty L.P. | $53.34 | 2021-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $50.99 | 2021 | |
| Almatica Pharma LLC | $44.00 | 2021-2025 | Loreev Xr, Teriparatide |
| Verona Pharma, INC. | $42.15 | 2025 | Ohtuvayre |
| Therapeuticsmd, INC. | $38.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $38.31 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $36.08 | 2025 | Neffy |
| Ani Pharmaceuticals, INC. | $36.08 | 2025 | Purified Cortrophin Gel |
| Kowa Pharmaceuticals America, INC. | $31.84 | 2023 | Seglentis, Livalo |
| Tonix Medicines, INC. | $29.34 | 2025 | Tonmya |
| Mayne Pharma Commercial LLC | $28.61 | 2023 | |
| Amarin Pharma, INC. | $28.18 | 2021 | |
| Esperion Therapeutics, INC. | $27.90 | 2021-2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $27.30 | 2021 | |
| Eisai INC. | $25.50 | 2023 | |
| Nestle Healthcare Nutrition INC. | $24.25 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $23.70 | 2021 | |
| Nevro Corp. | $21.57 | 2022 | |
| Gilead Sciences, INC. | $19.75 | 2025 | Yeztugo |
| Novartis Pharmaceuticals Corporation | $17.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.12 | 2022 | |
| Inogen, INC. | $11.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Gemelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.